Two biopharma giants sitting at opposite ends of the market's attention span.
Exxon vs. Chevron. One Reports July 24. One Reports July 31.
Both energy giants beat in Q1. The Q2 call is where the real story gets told.
The Only Number That Tells You If a Business Is Actually Any Good
ROIC separates the compounders from the capital destroyers.
Constellation Brands Is Down 47% From Its High. The Market Is Pricing a Business That No Longer Exists.
STZ just beat earnings, raised guidance, and still trades at 13x. The fear is real. So is the opportunity.
AeroVironment Just Had the Strongest Year in Its History. The Stock Is Still Down 34%.
Revenue grew 133% last quarter. A $500 million Army contract just landed.
Cameco Is Down From Its High. The Nuclear Trade Has Never Been Bigger.
AI's power problem just became uranium's biggest catalyst in decades.
SpaceX Joins the Nasdaq-100 in Two Days. The Forced Buying Is Already Priced In.
What happens to SPCX after the mechanical flow ends is the only question that matters now.
Europe’s Defense Boom Is Hitting a Wall
The spending is real. The question now is whether the companies can actually deliver.
The Dow Just Hit a Record. The Nasdaq Fell. That Split Is the Trade.
The rotation into value, financials, and industrials is accelerating faster than most investors realize.
Big Pharma Has $1.3 Trillion to Spend. The Clock Is Running.
A patent cliff with a known deadline is forcing the largest acquisition wave in biopharma history.